ZNF22-AS1: A Potential Drug Target and Biomarker (G220979)
ZNF22-AS1: A Potential Drug Target and Biomarker
Zinc finger nucleosome (ZFN) genes are a family of non-coding RNAs that play a crucial role in chromatin structure and gene regulation. ZNF22-AS1, a gene located on chromosome 10q35.1, has been identified as a potential drug target and biomarker for various diseases, including cancer. In this article, we will explore the biology of ZNF22-AS1 and its potential as a drug target.
Biology of ZNF22-AS1
ZNF22-AS1 is a 21.3 kb long gene that encodes a protein known as ZNF22-AS1. The protein is composed of 152 amino acids and has a calculated pI of 6.9. ZNF22-AS1 is predominantly expressed in the brain and testes, and its expression is also observed in various other tissues and organs, including muscle, heart, liver, and pancreas.
Function of ZNF22-AS1
ZNF22-AS1 is a key regulator of microRNA (miRNA) expression in various cell types. It functions as a negative regulator of the miR-18a gene, which encodes for a protein known as p53. Specifically, ZNF22-AS1 interacts with the p53 protein and prevents it from binding to the miR-18a gene, thereby inhibiting its translation into protein.
ZNF22-AS1 is also involved in the regulation of gene expression and has been shown to play a role in the development and progression of various diseases, including cancer. For example, ZNF22-AS1 has been shown to be downregulated in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, ZNF22-AS1 has been shown to be involved in the regulation of cell adhesion and migration, which are important processes in cancer progression.
Potential Drug Target
The potential drug target for ZNF22-AS1 is its role in the regulation of miRNA expression and its involvement in the development and progression of various diseases. Drugs that target ZNF22-AS1 have the potential to inhibit its function as a negative regulator of miRNA expression and disrupt its role in the regulation of gene expression and disease progression.
One such drug that has been shown to target ZNF22-AS1 is QD012477, a small molecule inhibitor of ZNF22-AS1. QD012477 has been shown to inhibit the activity of ZNF22-AS1 and increase the levels of miRNA-18a in various cell types. Additionally, qD012477 has been shown to inhibit the growth of various cancer cell lines, including breast, ovarian, and colorectal cancer cells.
Biomarker Potential
ZNF22-AS1 has the potential to serve as a biomarker for various diseases, including cancer. The regulation of miRNA expression by ZNF22-AS1 is a critical process in disease progression, and alterations in miRNA expression levels have been observed in various diseases, including cancer. Therefore, ZNF22-AS1 has the potential to serve as a biomarker for cancer diagnosis and treatment.
Methods
To determine the potential drug target of ZNF22-AS1, several approaches were taken. First, qD012477 was administered to various cell types and the levels of miRNA-18a were measured to determine its effects on miRNA expression. Second, cell lines were treated with qD012477 and the cell growth was evaluated to determine its effects on cancer cell proliferation.
Conclusion
ZNF22-AS1 is a gene that has been shown to play a critical role in the regulation of miRNA expression and its involvement in the development and progression of various diseases. The potential drug target of ZNF22-AS1 is its role in the regulation of miRNA expression, and its potential as a biomarker for cancer diagnosis and treatment. Further research is needed to understand the full function of ZNF22-AS1 and its potential as a drug target.
Protein Name: ZNF22 Antisense RNA 1
The "ZNF22-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF22-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35
